Hepatocellular carcinoma: Current treatment strategies

被引:10
作者
Shields A. [1 ]
Reddy K.R. [1 ]
机构
[1] Gastroenterology Division, Hospital of the University of Pennsylvania, Philadelphia, PA 19104
关键词
Hepatocellular Carcinoma; Tace; Live Donor Liver Transplantation; Percutaneous Ethanol Injection; Milan Criterion;
D O I
10.1007/s11938-005-0032-x
中图分类号
学科分类号
摘要
Hepatocellular carcinoma (HCC) is an increasingly prevalent clinical problem. The presence of cirrhosis in the majority of patients makes treatment difficult because both the stage of the tumor and the stage of cirrhosis must be taken into account. This is compounded by the difficulty in diagnosing HCC in the early stages, where treatment is most effective, and the lack of a globally accepted treatment policy. Liver transplantation and liver resection are the optimal treatments, with resection being preferred in patients with small lesions, clinically well-preserved liver function, and absence of portal hypertension. Patients unsuitable for these procedures, due to localized but large tumor bulk, are only treatable by ablative and palliative therapies. Ablation involves either thermal (preferably radiofrequency ablation) or chemical methods, with the choice of method being dependent on both the size and placement of the tumor and the operator. Ablation may also be used as a bridge to transplantation in centers where significant waiting times are anticipated. Tumors that are too large in size or number to ablate are treated with transarterial chemoembolization, involving the distribution of chemotherapeutic agents and the blocking of the blood supply to the tumor; this is not considered a curative therapy. Combination therapies may also be used. These treatment options need further evaluation for determination of the optimal course of therapy for individual patients. Copyright © 2005 by Current Science Inc.
引用
收藏
页码:457 / 466
页数:9
相关论文
共 60 条
  • [1] El-Serag H.B., Davila J.A., Petersen N.J., Et al., The continuing increase in the incidence of hepatocellular carcinoma in the United States, Ann Intern Med, 139, pp. 817-832, (2003)
  • [2] Parkin D.M., Bray F., Ferlay J., Et al., Estimating the world cancer burden: Globocon 2000, Int J Cancer, 94, pp. 153-156, (2001)
  • [3] El-Serag H.B., Hepatocellular carcinoma and hepatitis C in the United States, Hepatology, 36, (2002)
  • [4] Sangiovanni A., Del Ninno E., Fasani P., Et al., Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance, Gastroenterology, 126, pp. 1005-1014, (2004)
  • [5] Benvegnu L., Gios M., Boccato S., Et al., Natural history of compensated cirrhosis: A prospective study on the incidence and hierarchy of major complications, Gut, 53, pp. 744-749, (2004)
  • [6] Llovet J.M., Bru C., Bruix J., Prognosis of hepatocellular carcinoma: The BCLC staging classification, Semin Liver Dis, 19, pp. 329-338, (1999)
  • [7] Marrero J.A., Fontana R.J., Barrat A., Et al., Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort, Hepatology, 41, pp. 707-716, (2005)
  • [8] Burroughs A., Hochhauser D., Meyer T., Systemic treatment and liver transplantation for hepatocellular carcinoma: Two ends of the therapeutic spectrum, Lancet, 5, pp. 409-418, (2004)
  • [9] Carr B.I., Hepatic arterial 90Yttrium glass microspheres (Theraspheres) for unresectable hepatocellular carcinoma: Interim safety and survival data on 65 patients, Liver Transpl, 10, 2 SUPPL. 1, (2004)
  • [10] Trevisani F., De N.S., Rapaccini G., Et al., Semianual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: Effects on cancer stage and patient survival (Italian experience), Am J Gastroenterol, 97, pp. 734-744, (2002)